{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['11.1', '6.8']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Median Survival": "5.7",
                    "One-Year Survival": "4.2",
                    "Side Effects": "18%",
                    "FDA Approval": "1996"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 5.7]",
                    "[One-Year Survival, 4.2]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['11.1', '6.8']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "6.4",
                    "One-Year Survival": "6",
                    "Side Effects": "24%",
                    "FDA Approval": "2005"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 6.4]",
                    "[One-Year Survival, 6]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['11.1', '6.8']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Median Survival": "8.5",
                    "One-Year Survival": "6.7",
                    "Side Effects": "35%",
                    "FDA Approval": "2013"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 8.5]",
                    "[One-Year Survival, 6.7]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX *",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Median Survival": "11.1",
                    "One-Year Survival": "6.8",
                    "Side Effects": "48.4%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 11.1]",
                    "[One-Year Survival, 6.8]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX *",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Median Survival": "11.1",
                    "One-Year Survival": "6.8",
                    "Side Effects": "48.4%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 11.1]",
                    "[One-Year Survival, 6.8]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX *",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Median Survival": "11.1",
                    "One-Year Survival": "6.8",
                    "Side Effects": "48.4%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 11.1]",
                    "[One-Year Survival, 6.8]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX *",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Median Survival": "11.1",
                    "One-Year Survival": "6.8",
                    "Side Effects": "48.4%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 11.1]",
                    "[One-Year Survival, 6.8]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX *",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Median Survival": "11.1",
                    "One-Year Survival": "6.8",
                    "Side Effects": "48.4%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 11.1]",
                    "[One-Year Survival, 6.8]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX *",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Median Survival": "11.1",
                    "One-Year Survival": "6.8",
                    "Side Effects": "48.4%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 11.1]",
                    "[One-Year Survival, 6.8]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX *",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Median Survival": "11.1",
                    "One-Year Survival": "6.8",
                    "Side Effects": "48.4%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 11.1]",
                    "[One-Year Survival, 6.8]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['11.1', '6.8']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Median Survival": "10",
                    "One-Year Survival": "5",
                    "Side Effects": "36%",
                    "FDA Approval": "n/a"
                },
                "measures": "[Treatment, FDA Approved]",
                "outcomes": [
                    "[Median Survival, 10]",
                    "[One-Year Survival, 5]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                    "Toxicity": "Grade 3 or Grade 4 NCI",
                    "Survival": "9.5 months"
                },
                "measures": "[Citation, NCI Toxicity]",
                "outcomes": "[Survival, 9.5 months]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Caption": "Summary of recent trial data for pancreatic cancer treatments"
                },
                "measures": "[Caption, Pancreatic Cancer Treatments]",
                "outcomes": ""
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        }
    ],
    "total_extracted_claims": 7,
    "total_ground_truth_claims": 10,
    "number_of_matches": 1
}